February

Safe Online Pharmacies (February 28, 2025)
How do I know if a medication I purchased online is safe?

Groff NA Hemplex LLC (PDF) (February 27, 2025)

Sharp Clinical Services, LLC (PDF) (February 26, 2025)

Catalent Pharma Solutions, LLC (PDF) (February 26, 2025)

S&B Pharma LLC DBA Norac Pharma (PDF) (February 26, 2025)

Jason Weakley R.N., A.P.R.N.; Decision and Order (PDF) (February 21, 2025)

Final Rule: Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients (PDF) (February 19, 2025)

Scottsdale Research Institute (PDF) (February 18, 2025)

Scottsdale Research Institute (PDF) (February 18, 2025)

Mylan Pharmaceuticals, Inc. (PDF) (February 18, 2025)

Patheon API Inc. (PDF) (February 18, 2025)

Janssen Pharmaceuticals, Inc. (PDF) (February 18, 2025)

Purisys, LLC (PDF) (February 18, 2025)

Lonza Tampa, LLC (PDF) (February 18, 2025)

Robert L. Carter, D.D.S.; Decision and Order (PDF) (February 14, 2025)

Yogesh Patel, M.D.; Decision and Order (PDF) (February 14, 2025)

Benuvia Operations, LLC (PDF) (February 13, 2025)

Veranova, L.P. (PDF) (February 13, 2025)

Purisys, LLC (PDF) (February 13, 2025)

University of Kentucky Cannabis Center (PDF) (February 13, 2025)

Maridose LLC (PDF) (February 13, 2025)

Mylan Inc. (PDF) (February 13, 2025)

Janssen Pharmaceuticals Inc. (PDF) (February 13, 2025)

David Bockoff, M.D.; Decision and Order (PDF) (February 10, 2025)

Massoud Amini, M.D.; Decision and Order (PDF) (February 7, 2025)

Herold Pierre-Louis, P.A.; Decision and Order (PDF) (February 7, 2025)

James T. Craig, D.D.S.; Decision and Order (PDF) (February 7, 2025)

January 2025

Organic Consultants LLC DBA Cascade Chemistry (PDF) (January 31, 2025)

Medi-Physics Inc. DBA GE Healthcare (PDF) (January 31, 2025)

Catalent Greenville, Inc. (PDF) (January 31, 2025)

30-Day Notice: Recordkeeping for Electronic Prescriptions for Controlled Substances (PDF) (January 30, 2025)

Vici Health Sciences, LLC (PDF) (January 28, 2025)

Aveva Drug Delivery Systems, Inc. (PDF) (January 28, 2025)

Noramco (PDF) (January 24, 2025)

VHG Labs DBA LGC Standards (PDF) (January 24, 2025)

Veranova, L.P. (PDF) (January 24, 2025)

Xubex Community Pharmacy; Decision and Order (PDF) (January 23, 2025)

Neumann's Pharmacy, LLC; Decision and Order (PDF) (January 23, 2025)

Groff Health, Inc. (PDF) (January 21, 2025)

Siegfried USA, LLC (PDF) (January 21, 2025)

Invizyne Technologies, Inc. (PDF) (January 21, 2025)

Final Rule: Continuity of Care via Telemedicine for Veterans Affairs Patients (PDF) (January 17, 2025)

Final Rule: Expansion of Buprenorphine Treatment via Telemedicine Encounter (PDF) (January 17, 2025)

Proposed Rule: Special Registrations for Telemedicine and Limited State Telemedicine Registrations (PDF) (January 17, 2025)

Laura M. Bellew, N.P.; Decision and Order (PDF) (January 17, 2025)

Kim Routh, D.O.; Decision and Order (PDF) (January 10, 2025)

December

Temporary Rule: Extension of Temporary Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act (PDF) (December 30, 2024)

Proposed Rule: Placement of 4-Chloromethcathinone in Schedule I (PDF) (December 30, 2024)

Proposed Rule: Placement of Seven Specific Fentanyl-Related Substances in Schedule I (PDF) (December 30, 2024)

Soroosh Armandi, D.O.; Decision and Order (PDF) (December 30, 2024)

Maria Dewitt, N.P.; Decision and Order (PDF) (December 30, 2024)

Robert Esser, D.D.S.; Decision and Order (PDF) (December 30, 2024)

Matthew Okeke, M.D.; Decision and Order (PDF) (December 30, 2024)

Kevin Petersen, M.D.; Decision and Order (PDF) (December 30, 2024)

Jason Lee Ray, PA-C; Decision and Order (PDF) (December 30, 2024)

Shiva Akula, M.D.; Decision and Order (PDF) (December 30, 2024)

Samreen Riaz, D.D.S.; Decision and Order (PDF) (December 30, 2024)

Jeffrey W. Young, Jr., N.P.; Decision and Order (PDF) (December 30, 2024)

Irvine Labs Inc. (PDF) (December 30, 2024)

Siegfried USA, LLC (PDF) (December 30, 2024)

Curia New York, Inc. (PDF) (December 30, 2024)

Leading Pharma LLC (PDF) (December 18, 2024)

Final Order: Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024 (PDF) (December 17, 2024)

Final Order: Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2025 (PDF) (December 17, 2024)

National Center for Natural Products Research (PDF) (December 13, 2024)

Groff NA Hemplex LLC (PDF) (December 13, 2024)

30-Day Notice: Application for Registration and Application for Registration Renewal; DEA Forms 224, 224A (PDF) (December 12, 2024)

Kinetochem LLC (PDF) (December 6, 2024)

Navinta LLC (PDF) (December 6, 2024)

Organic Standards Solutions International, LLC (PDF) (December 6, 2024)

Noramco (PDF) (December 6, 2024)

Curia Wisconsin, Inc. (PDF) (November 29, 2024)

Cambrex Charles City (PDF) (November 29, 2024)

November

60-Day Notice: Recordkeeping for Electronic Prescriptions for Controlled Substances (PDF) (November 26, 2024)

Experic LLC (PDF) (November 26, 2024)

Cayman Chemical Company (PDF) (November 26, 2024)

Organix Chemistry Solutions, LLC (PDF) (November 26, 2024)

National Center for Natural Products Research (PDF) (November 26, 2024)

Isosciences, LLC (PDF) (November 26, 2024)

Temporary Rule: Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (PDF) (November 19, 2024)

October

Proposed Rule: Possible Control of Phenethyl Bromide as a List I Chemical (PDF) (October 28, 2024)

Final Rule: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I (PDF) (October 25, 2024)

30-Day Notice: Exempt Chemical Preparations Under the Controlled Substance Act (PDF) (October 25, 2024)

David Carlos Rodriguez, M.D.; Decision and Order (PDF) (October 23, 2024)

BRX Pharmacy; Decision and Order (PDF) (October 23, 2024)

Itani Family Pharmacy, PLC; Decision And Order (PDF) (October 23, 2024)

Dale Fitzpatrick, M.D.; Decision and Order (PDF) (October 23, 2024)

Irvine Labs, Inc. (PDF) (October 23, 2024)

Mylan Technologies Inc. (PDF) (October 23, 2024)

Halo Pharmaceutical Inc. (PDF) (October 23, 2024)

Irvine Labs, Inc. (PDF) (October 23, 2024)

Final Rule: Placement of Ethylphenidate in Schedule I (PDF) (October 22, 2024)

Neeraj B. Shah, M.D.; Decision and Order (PDF) (October 21, 2024)

Michael Berman, D.O.; Decision and Order (PDF) (October 11, 2024)

William J. Mack, M.D.; Decision and Order (PDF) (October 11, 2024)

Robert P. Hansen, M.D.; Decision and Order (PDF) (October 11, 2024)

Janet S. Pettyjohn, D.O.; Decision and Order (PDF) (October 11, 2024)

Salman Akbar, M.D.; Decision and Order (PDF) (October 10, 2024)

Midtown Specialty RX; Decision and Order (PDF) (October 10, 2024)

Halowells Pharmacy; Decision and Order (PDF) (October 10, 2024)

Merry Alice Troupe, N.P.; Decision and Order (PDF) (October 8, 2024)

60-Day Notice: Application for Registration and Application for Registration Renewal; DEA Forms 224, 224A (PDF) (October 7, 2024)

Curia Wisconsin, Inc. (PDF) (October 1, 2024)

Fresenius Kabi USA, LLC (PDF) (October 1, 2024)